Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Jazz Pharmaceuticals 2025 Second Quarter Earnings Conference Call.
Jazz Pharmaceuticals Plc (JAZZ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 1,706,469 | $181,090,490 | 10.72% | |
| 2. | Vestal Point Capital Ryan Wilder | 1,200,000 | $127,344,000 | 6.7% | |
| 3. | Renaissance Technologies Jim Simons | 900,368 | $95,547,052 | -14% | 0.13% |
| 4. | AQR Capital Management Cliff Asness | 794,770 | $84,341,009 | +63% | 0.07% |
| 5. | GMT Capital Thomas E. Claugus | 768,400 | $81,542,608 | +15% | 3.41% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $103.00 | 1,621 | $166,961.54 | 101,621 | 2025-05-12 | Filing | |
| $99.71 | 100 | $9,971.00 | 100,000 | 2025-05-09 | Filing | |
| $98.91 | 19,216 | $1,900,677.62 | 99,900 | 2025-05-09 | Filing | |
| $98.10 | 80,684 | $7,915,471.55 | 80,684 | 2025-05-09 | Filing | |
| $119.65 | 12,000 | $1,435,800.00 | 27,932 | 2024-03-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $113.21 | 1,000 | $113,210.00 | 435,973 | 2025-08-01 | Filing | |
| $110.00 | 500 | $55,000.00 | 436,973 | 2025-07-01 | Filing | |
| $105.26 | 500 | $52,630.00 | 437,473 | 2025-07-01 | Filing | |
| $110.00 | 500 | $55,000.00 | 437,973 | 2025-06-03 | Filing | |
| $107.90 | 500 | $53,950.00 | 438,473 | 2025-06-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,090,872 | $646,363,337 | 0.01% | |
| 2. | 5,799,716 | $615,465,860 | 0.01% | |
| 3. | 2,544,522 | $270,024,675 | 0.04% | |
| 4. | 2,537,837 | $269,321,654 | 0.06% | |
| 5. | 1,935,385 | $205,383,056 | 0.01% |
News See All
Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains ‘Buy’ Rating
On July 22, 2025, Morgan Stanley maintained its ‘Buy’ rating on JAZZ. However, the analyst lowered its price target slightly from $166 to $165.
10 Most Undervalued Foreign Stocks to Buy According to Analysts
The dominance of U.S. stocks within the investment landscape has existed for years, with the S&P 500 index leading with an impressive 14.20% annualized return over the last 15 years.
Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the 7 most undervalued pot stocks to buy according to analysts.
7 Most Undervalued Pot Stocks To Buy According To Analysts
The global cannabis market was worth $26.86 billion in 2022, Spherical Insights & Consulting data shows. Three years later, Mordor Intelligence valued the market at $44.60 billion.
Avadel Pharmaceuticals Receives Unanimous Appeals Court Affirmation for LUMRYZ FDA Approval
Avadel Pharmaceuticals (NASDAQ:AVDL) is one of the most undervalued small-cap stocks to buy according to analysts.
Jazz Pharmaceuticals' Ziihera Receives Conditional European Approval for Advanced Biliary Tract Cancer
Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the best high short interest stocks with huge upside potential.
10 Best High Short Interest Stocks With Huge Upside Potential
Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' on July 2 to discuss the market's momentum as stocks began the second half of the year. Yoder confirmed her continued...
Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the 30 stocks expected to beat the market by 20 percentage points this year.
30 Stocks Expected To Beat the Market By 20 Percentage Points This Year
The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June.
Billionaire Hedge Funds
